We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters (WAT) Q4 Earnings & Sales Beat Estimates, Fall Y/Y
Read MoreHide Full Article
Waters Corporation (WAT - Free Report) reported fourth-quarter 2023 non-GAAP earnings of $3.62 per share, beating the Zacks Consensus Estimate by 1.7%. However, the bottom line declined 5.7% on a year-over-year basis.
Net sales of $819.5 million topped the Zacks Consensus Estimate of $813.7 million. The figure fell 4.5% on a reported basis and 8% at constant currency from the year-ago quarter’s readings.
Softness in the pharmaceutical, industrial, and government and academic markets was a major concern. Also, weakening momentum in Asia remained a headwind.
Sluggishness in the Waters and TA segments was a negative.
Nevertheless, growing momentum across the Americas and Europe was a positive.
Waters Corporation Price, Consensus and EPS Surprise
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: WAT operates under two organized segments, namely Waters and TA.
The Waters segment (87% of net sales) generated sales worth $716.93 million, down 5% year over year. Sales in the TA segment were $102.54 million (13%), reflecting 1% year-over-year decline.
By Products & Services: The division comprises three segments, namely Instruments, Services and Chemistry.
Instruments sales (47%) were $397.2 million, declining 14% on a year-over-year basis.
Services registered sales (35%) worth $278.9 million, climbing 9% year over year.
Chemistry sales (18%) totaled $143.4 million, growing 3% year over year.
Moreover, the Services and Chemistry segments jointly generated recurring revenues of $422.3 million, up 7% year over year.
By Markets: Waters serves three end markets, such as Pharmaceutical, Industrial, and Governmental & Academic.
The Pharmaceutical market (56%) generated sales of $463.7 million, which decreased 6% on a year-over-year basis.
The Industrial market’s (33%) sales were $260.25 million, down 3% year over year.
Governmental & Academic market (11%) generated $95.53 million of total sales. The figure plunged 2% year over year.
By Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia (33%) generated $261.9 million in sales, down 18% on a year-over-year basis.
Sales in the Americas (36%) generated $303.7 million, growing 4% year over year. The United States registered 12% year-over-year improvement in sales.
Europe (31%) generated $253.8 million in sales, up 3% year over year.
Operating Details
In the fourth quarter, non-GAAP selling and administrative expenses were $172.95 million, down 0.03% year over year. As a percentage of net sales, the figure expanded 100 basis points (bps) on a year-over-year basis.
Research and development spending of $44.4 million decreased 8.1% year over year. As a percentage of net sales, the figure contracted 20 bps year over year.
Adjusted operating margin was 34.9%, which expanded 120 bps year over year.
Balance Sheet & Cash Flow
As of Dec 31, 2023, cash, cash equivalents and investments were $395.97 million, up from $337.3 million as of Sep 30, 2023.
Waters generated cash from operations of $230.12 million in the reported quarter, up from $157.8 million in the prior quarter.
WAT recorded a free cash flow of $191.65 million in the fourth quarter.
Guidance
For first-quarter 2024, Waters expects non-GAAP earnings of $2.05-$2.15 per share. The Zacks Consensus Estimate is pegged at $2.49.
Management anticipates organic sales to decline 11-9% on a constant-currency basis. WAT projects sales to decline by 1% due to unfavorable foreign exchange fluctuations. Wyatt transaction is estimated to increase sales by 3.5%.
On a reported basis, total sales are predicted to decline 8.5-6.5%. The Zacks Consensus Estimate is pegged at $694.16 million.
For 2024, Waters anticipates non-GAAP earnings of $11.75-$12.05 per share. This includes a foreign exchange headwind of 1%. The Zacks Consensus Estimate is pegged at $12.00.
Waters projects 2024 organic sales growth of -0.5-1.5% on a constant-currency basis. Wyatt transaction is expected to increase sales by 1.3%.
On a reported basis, total sales are suggested to grow 0-2%. The Zacks Consensus Estimate is pegged at $3.02 billion.
Image: Bigstock
Waters (WAT) Q4 Earnings & Sales Beat Estimates, Fall Y/Y
Waters Corporation (WAT - Free Report) reported fourth-quarter 2023 non-GAAP earnings of $3.62 per share, beating the Zacks Consensus Estimate by 1.7%. However, the bottom line declined 5.7% on a year-over-year basis.
Net sales of $819.5 million topped the Zacks Consensus Estimate of $813.7 million. The figure fell 4.5% on a reported basis and 8% at constant currency from the year-ago quarter’s readings.
Softness in the pharmaceutical, industrial, and government and academic markets was a major concern. Also, weakening momentum in Asia remained a headwind.
Sluggishness in the Waters and TA segments was a negative.
Nevertheless, growing momentum across the Americas and Europe was a positive.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
Top Line in Detail
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: WAT operates under two organized segments, namely Waters and TA.
The Waters segment (87% of net sales) generated sales worth $716.93 million, down 5% year over year. Sales in the TA segment were $102.54 million (13%), reflecting 1% year-over-year decline.
By Products & Services: The division comprises three segments, namely Instruments, Services and Chemistry.
Instruments sales (47%) were $397.2 million, declining 14% on a year-over-year basis.
Services registered sales (35%) worth $278.9 million, climbing 9% year over year.
Chemistry sales (18%) totaled $143.4 million, growing 3% year over year.
Moreover, the Services and Chemistry segments jointly generated recurring revenues of $422.3 million, up 7% year over year.
By Markets: Waters serves three end markets, such as Pharmaceutical, Industrial, and Governmental & Academic.
The Pharmaceutical market (56%) generated sales of $463.7 million, which decreased 6% on a year-over-year basis.
The Industrial market’s (33%) sales were $260.25 million, down 3% year over year.
Governmental & Academic market (11%) generated $95.53 million of total sales. The figure plunged 2% year over year.
By Geography: Waters’ operating regions include Asia, the Americas and Europe.
Asia (33%) generated $261.9 million in sales, down 18% on a year-over-year basis.
Sales in the Americas (36%) generated $303.7 million, growing 4% year over year. The United States registered 12% year-over-year improvement in sales.
Europe (31%) generated $253.8 million in sales, up 3% year over year.
Operating Details
In the fourth quarter, non-GAAP selling and administrative expenses were $172.95 million, down 0.03% year over year. As a percentage of net sales, the figure expanded 100 basis points (bps) on a year-over-year basis.
Research and development spending of $44.4 million decreased 8.1% year over year. As a percentage of net sales, the figure contracted 20 bps year over year.
Adjusted operating margin was 34.9%, which expanded 120 bps year over year.
Balance Sheet & Cash Flow
As of Dec 31, 2023, cash, cash equivalents and investments were $395.97 million, up from $337.3 million as of Sep 30, 2023.
Waters generated cash from operations of $230.12 million in the reported quarter, up from $157.8 million in the prior quarter.
WAT recorded a free cash flow of $191.65 million in the fourth quarter.
Guidance
For first-quarter 2024, Waters expects non-GAAP earnings of $2.05-$2.15 per share. The Zacks Consensus Estimate is pegged at $2.49.
Management anticipates organic sales to decline 11-9% on a constant-currency basis. WAT projects sales to decline by 1% due to unfavorable foreign exchange fluctuations. Wyatt transaction is estimated to increase sales by 3.5%.
On a reported basis, total sales are predicted to decline 8.5-6.5%. The Zacks Consensus Estimate is pegged at $694.16 million.
For 2024, Waters anticipates non-GAAP earnings of $11.75-$12.05 per share. This includes a foreign exchange headwind of 1%. The Zacks Consensus Estimate is pegged at $12.00.
Waters projects 2024 organic sales growth of -0.5-1.5% on a constant-currency basis. Wyatt transaction is expected to increase sales by 1.3%.
On a reported basis, total sales are suggested to grow 0-2%. The Zacks Consensus Estimate is pegged at $3.02 billion.
Zacks Rank & Key Picks
Currently, Waters has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Arista Networks (ANET - Free Report) , Badger Meter (BMI - Free Report) and AMETEK (AME - Free Report) . Arista Networks sports a Zacks Rank #1 (Strong Buy), and Badger Meter and AMETEK carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks shares have surged 110.5% in the past year. The long-term earnings growth rate for ANET is projected at 19.77%.
Badger Meter shares have gained 15.7% in the past year. The long-term earnings growth rate for BMI is anticipated at 12.27%.
AMETEK shares have risen 13.5% in the past year. The long-term earnings growth rate for AME is pegged at 9.58%.